BCA
BEAM icon

Berman Capital Advisors’s Beam Therapeutics BEAM Stock Holding History

Berman Capital Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Buy
+5
New +$502 ﹤0.01% 2065

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's BEAM Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Beam Therapeutics (BEAM) in Q3 2021: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2065 among its holdings.

231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Berman Capital Advisors held 5 shares of Beam Therapeutics worth $0 as of Q3 2021.
  • Beam Therapeutics was a new Berman Capital Advisors position in Q3 2021.
  • Beam Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2065 holding.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.